Cochlear Implants
Clinical Coverage Criteria

Overview
A Cochlear implant device is an electronic instrument, part of which is implanted surgically to stimulate auditory nerve fibers, and part of which is worn or carried by the individual to capture, analyze, and code sound. Cochlear implant devices are available in single-channel and multi-channel models. The purpose of implanting the device is to provide awareness and identification of sounds and to facilitate communication for persons who are moderately to profoundly hearing impaired.

Policy
This Policy applies to the following Fallon Health products:
☒ Commercial
☒ Medicare Advantage
☒ MassHealth ACO
☒ NaviCare
☒ PACE

Prior authorization is required.

Covered Indications
1. Bilateral pre- or post-linguistic, sensorineural, moderate-to-profound hearing loss in individuals who demonstrate limited benefit from amplification. Limited benefit from amplification is defined by test scores of less than or equal to 40% correct in the best-aided listening condition on tape-recorded tests of open-set sentence cognition.

Criteria (ALL must be met):
- Diagnosis of bilateral moderate-to-profound sensorineural hearing impairment (hearing threshold of pure-tone average of 70 dB (decibels) hearing loss or greater at 500, 1000, and 2000 Hz) with limited benefit from appropriate hearing (or vibrotactile) aids;
- Cognitive ability to use auditory clues and a willingness to undergo an extended program of rehabilitation;
- Freedom from middle ear infection, an accessible COCHLEAR lumen that is structurally suited to implantation, and freedom from lesions in the auditory nerve and acoustic areas of the central nervous system;
- No contraindications to surgery

For Medicare Advantage plan members:
In accordance with National Coverage Determination for Cochlear Implantation (50.3), effective for dates of service on or after April 4, 2005, cochlear implantation is covered for Medicare Advantage plan with hearing test scores of greater than 40% and less than or equal to 60 when the plan member is enrolled in:
- An FDA-approved category B investigational device exemption (IDE) clinical trial as defined at 42 CFR 405.201 (CMS-approved IDE studies are listed on the CMS website at: https://www.cms.gov/Medicare/Coverage/IDE/Approved-IDE-Studies),
- A clinical trial under CMS Clinical Trial Policy as defined at section 310.1 of the National Coverage Determinations Manual, or
A prospective, controlled comparative trial approved by CMS as consistent with the evidentiary requirements for National Coverage Analyses and meeting specific quality standards. CMS-approved clinical trials are listed on the CMS website at: https://www.cms.gov/Medicare/Coverage/Coverage-with-Evidence-Development/Cochlear-Implantation.

Patient eligibility criteria for any of the above study types include members who meet all of these five selection criteria:
1. Diagnosis of bilateral moderate-to-profound sensorineural hearing impairment with limited benefit from appropriate hearing (or vibrotactile) aids;
2. Cognitive ability to use auditory clues and a willingness to undergo an extended program of rehabilitation;
3. Freedom from middle ear infection, an accessible cochlear lumen that is structurally suited to implantation, and freedom from lesions in the auditory nerve and acoustic areas of the central nervous system;
4. No contraindications to surgery; and
5. The device must be used in accordance with Food and Drug Administration (FDA)-approved labeling.

Claims for services related to clinical trials must be submitted with the NCT Identifier, ICD-10-CM diagnosis code Z00.6 in either the primary/secondary position and modifier Q0/Q1 as appropriate.

Exclusions

- Non-covered indications: Unilateral hearing loss with or without tinnitus.
- Upgrades of an existing, functioning external system to achieve aesthetic improvement, such as smaller profile components or a switch from a body-worn, external sound processor to a behind-the-ear model.
- Upgrades of an existing, functional system for technological improvements that do not statistically significantly improve the clinical outcome of doing basic ADLs.
- Replacement of a device that is out of warranty but still functioning to address the member's typical needs.

Coding

The following codes are included below for informational purposes only; inclusion of a code does not constitute or imply coverage.

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>69930</td>
<td>Cochlear device implantation, with or without mastoidectomy</td>
</tr>
<tr>
<td>L8614</td>
<td>Cochlear device, includes all internal and external components</td>
</tr>
<tr>
<td>L8619</td>
<td>Cochlear implant external speech processor, replacement</td>
</tr>
</tbody>
</table>

References


Policy history

Origination date: 01/01/2014
Approval(s): Technology Assessment Committee 10/23/2013 (Adopted Interqual Criteria) 01/28/2015 (annual review), 01/27/2016 (annual review), 01/25/2017 (annual review), 01/24/2018 (annual review), 01/23/2019 (annual review), 05/27/2020 (adopted Fallon Health criteria)
provisions for coverage and exclusions regardless of medical necessity. Please consult the product’s Evidence of Coverage for exclusions or other benefit limitations applicable to this service or supply. If there is any discrepancy between this policy and a member’s benefit plan, the provisions of the benefit plan will govern. However, applicable state mandates take precedence with respect to fully-insured plans and self-funded non-ERISA (e.g., government, school boards, church) plans. Unless otherwise specifically excluded, federal mandates will apply to all plans. For Medicare and Medicaid members, this policy will apply unless Medicare and Medicaid policies extend coverage beyond this policy.